ENTA Share Price Performance
US$14.09
6.08 (75.91%)
Price US$14.09
Share Pricen/a
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?
Nov 26
Enanta Pharmaceuticals, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
ENTA Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Enanta Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 09, 2026
- -2.84
- 100.00%
- -125.36%
- 221.2%
About ENTA
- Founded
- 1995
- Employees
- 120
- CEO
- WebsiteView website
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
